New High-Volume Shipping System, Improving
Patient Accessibility, Will Be Showcased by Cryoport Systems at
Phacilitate's Advanced Therapies Week in Dallas
NASHVILLE,
Tenn., Jan. 21, 2025 /PRNewswire/ -- Cryoport,
Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader
in supply chain solutions for the life sciences, today unveiled its
Cryoport Express® Cryogenic HV3 Shipping System ("HV3"),
the Company's newest product innovation in Cryoport's comprehensive
portfolio of global end-to-end temperature-controlled supply chain
offerings.
The HV3 ensures unparalleled protection and
accessibility for biologics and other temperature-sensitive
materials. Its unique rectilinear design eliminates the need for
palletization (securing goods on a pallet for transportation) and
provides the ability to transport critical life science materials
on narrow-bodied aircraft, ensuring compliance with regional
carriers and reducing flight rejections and delays. As a result,
the HV3 increases the number of available shipping lanes, which
will improve patient access and enable life-saving therapies to
reach patients in underserved areas.
This newly developed shipping system offers
enhanced payload protection and resilience during transport. With
additional space for non-temperature sensitive accessories and
documentation, the HV3 also improves storage efficiency through the
ability to stack and nest the shippers, making it more
cost-effective and user-friendly. Full compliance with airline
requirements plus an integrated condition and location monitoring
system provides full Chain of Compliance®. Engineered to
meet the specific needs of advanced therapies, the HV3
ensures enhanced payload security and superior temperature control,
maintaining payload integrity and extended temperature stability at
-150°C or lower.
The HV3's structure also enhances mobility with
its robust wheels and an integrated front-facing handle, improving
accessibility at point-of-care sites. Its design also provides for
scalability or higher density storage capabilities at manufacturing
and clinical sites. While improving overall safety for clinicians
and operators, these improvements enable more efficient handling
(and storage) at point-of-care sites, contract development and
manufacturing organizations (CDMO's), and other storage locations,
reducing the need for additional site-based resources. The HV3 is
also designed to be used with Cryoport's
Safepak® System. The
Safepak® System is a purpose built solution that
utilizes non-metallic, soft materials to minimize the effects of
vibration and shock during the transport of cell and gene
therapies.
"We are committed to anticipating industry
challenges and continuously evolving our solutions to meet the
critical needs of our clients and the patients they serve," said
Jerrell Shelton, CEO, Cryoport.
"With the introduction of the Cryoport Express®
Cryogenic HV3 Shipping System, we are improving patient access to
vital cell therapies in smaller cities and remote areas, which will
ultimately improve patient outcomes at large."
The Cryoport Express® Cryogenic HV3
Shipping System will be showcased at Phacilitate's Advanced
Therapies Week at booth 141, and featured during a panel
discussion on patient-centric advancements in the advanced
therapies supply chain on January 22,
2025, in Dallas, Texas,
from 11 a.m. to 12 p.m. CST.
"With its innovative structure, improved
mobility, enhanced protection and accessibility improvements, we
believe the HV3 will be well-received by companies looking for
user-centric solutions to the unique and considerable logistical
challenges of transporting advanced therapies globally," added
Mike Dybicz, Chief Product
Development Officer, Cryoport Systems. "We are passionate about
providing novel solutions to meet market, user and biologic product
specific transport/protection challenges and are united in our
shared goal of enhancing patient access to critical, life-saving
therapies."
About Cryoport, Inc.
Cryoport,
Inc. (Nasdaq: CYRX), is a global leader in supply chain
solutions for the Life Sciences with an emphasis on cell & gene
therapies. Cryoport enables manufacturers, contract manufacturers
(CDMO's), contract research organizations (CRO's), developers, and
researchers to carry out their respective business with products
and services that are designed to derisk services and provide
certainty. We provide a broad array of supply chain solutions for
the life sciences industry. Through our platform of critical
products and solutions including advanced temperature-controlled
packaging, informatics, specialized bio-logistics services,
bio-storage, bio-services, and cryogenic systems, we are "Enabling
the Future of Medicine™" worldwide, through our innovative systems,
compliant procedures, and agile approach to superior supply chain
management.
Our corporate headquarters, located in
Nashville, Tennessee, is
complemented by over 50 global locations in 17 countries, with key
sites in the United States,
United Kingdom, France, the
Netherlands, Belgium,
Portugal, Germany, Japan, Australia, India, and China.
For more information, visit
www.cryoportinc.com or follow via LinkedIn at
https://www.linkedin.com/company/cryoportinc or @cryoport on
X, formerly known as Twitter at www.twitter.com/cryoport for
live updates.
Forward-Looking
Statements
Statements in this press release which are
not purely historical, including statements regarding Cryoport's
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, those related to the
launch of the Cryoport Express® Cryogenic HV3 Shipping
System, including the potential impact on future revenue and
revenue streams. It is important to note that Cryoport's
actual results could differ materially from those in any such
forward-looking statements. Factors that could cause actual results
to differ materially include, but are not limited to, risks and
uncertainties associated with the effect of changing economic and
geopolitical conditions, supply chain constraints, inflationary
pressures, the effects of foreign currency fluctuations, trends in
the products markets, variations in Cryoport's cash flow, market
acceptance risks, and technical development risks. Cryoport's
business could be affected by other factors discussed in Cryoport's
SEC reports, including in the "Risk Factors" section of its most
recently filed periodic reports on Form 10-K and Form 10-Q, as well
as in its subsequent filings with the SEC. The forward-looking
statements contained in this press release speak only as of the
date hereof and Cryoport cautions investors not to place undue
reliance on these forward-looking statements. Except as required by
law, Cryoport disclaims any obligation, and does not undertake to
update or revise any forward-looking statements in this press
release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cryoport-unveils-state-of-the-art-cryogenic-shipping-system-for-transporting-lifesaving-biologics-and-temperature-sensitive-therapies-302355899.html
SOURCE Cryoport, Inc.